Clinical Trials
65 trialsTRIDENT-1
Turning Point Therapeutics, Inc.
SUNRAY-01
Eli Lilly and Company
FOREFRONT
AstraZeneca
LADOGA
AstraZeneca
RehabKBP
University Hospital, Toulouse
NADIM-ADJUVANT
Fundación GECP
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Stanford University
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
Weill Medical College of Cornell University
LIBRETTO-001
Eli Lilly and Company
ETCABIO
University Hospital, Angers
REVIVE
AstraZeneca
AcceleRET-Lung
Hoffmann-La Roche
LOTOS
AstraZeneca
VALOR
VA Office of Research and Development
EBNK-ST-001
Essen Biotech
Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) Study
AstraZeneca
LIBRETTO-121
Eli Lilly and Company
Tale EAP
Nuvation Bio Inc.
ImHADom
Centre Hospitalier de PAU
Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)
Qilu Pharmaceutical Co., Ltd.
BCBPoumon
Institut du Cancer de Montpellier - Val d'Aurelle
ARROW
Hoffmann-La Roche
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
APOLO
Fundación GECP
Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients
Fundación GECP
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
Blueprint Medicines Corporation
(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
Blueprint Medicines Corporation
DURVABREIZH
University Hospital, Brest
CombHADom
Centre Hospitalier de PAU
A Phase â…¡ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC
Nanfang Hospital, Southern Medical University
Stereotactic
University Hospital, Strasbourg, France
Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer
Weill Medical College of Cornell University
CANUT-2
Hospices Civils de Lyon
ALpha-T
Hoffmann-La Roche
(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC
Blueprint Medicines Corporation
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors
Shanghai Yunying Medical Technology
A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC
Jiangsu HengRui Medicine Co., Ltd.
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
WiZen
Technische Universität Dresden
LUCAS
Ceska Lekarska Spolecnost Jana Evangelisty Purkyne z.s.
ENCORE110
Syndax Pharmaceuticals
Kinetics of Circulating Tumoral Cells in Bronchial Primitive Cancer
Fondation Hôpital Saint-Joseph
External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC
Blueprint Medicines Corporation
Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)
H. Lee Moffitt Cancer Center and Research Institute
EPIC
University of Turin, Italy
OnkoFit II
University Hospital Tuebingen
A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC
Jiangsu HengRui Medicine Co., Ltd.
Tumour Registry Lung Cancer (TLK)
iOMEDICO AG
Comparison of Post-operative Pain and Quality of Life Between Subxiphoid and Intercostal VATS for Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
PANORAMA
AstraZeneca